The Patent Finder

Miami University

18 patents currently held · Updated Nov 16, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
5
Ending by 2030
Jul 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 13, 2026
    The maintenance fee for Donor plasmid vectors (US 11,674,157) comes due Dec 13, 2026. Unpaid by Jun 14, 2027, it lapses early.
  • 1 fee due Feb 1, 2027
    The maintenance fee for Non-invasive diagnostic systems and methods for using the same (US 11,714,114) comes due Feb 1, 2027. Unpaid by Aug 2, 2027, it lapses early.
  • 1 fee due Jul 12, 2027
    The maintenance fee for Use of HGMA-targeted phosphorothioate DNA aptamers to suppress carcinogenic activity and increase sensitivity to chemotherapy agents in human cancer cells (US 9,233,119) comes due Jul 12, 2027. Unpaid by Jan 12, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 term has ended since Aug 18, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 7,534,947Oboe reed gouge apparatus
In force
 · From the USPTO record
In forceFrom the USPTO record
US 7,669,364Devices, kits, and methods for providing protection to plants
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,455,191Cell transdifferentiation into brown adipocytes
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,835,112Cell transdifferentiation into brown adipocytes
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,808,324Hand pressure device to diminish gag reflex response
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,432,249Advanced transitional cup
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,492,470Use of HMGA-targeted phosphorothioate DNA aptamers to suppress carcinogenic activity and increase sensitivity to chemotherapy agents in human cancer cells
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,233,119Use of HGMA-targeted phosphorothioate DNA aptamers to suppress carcinogenic activity and increase sensitivity to chemotherapy agents in human cancer cells
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,909,106Recombinant baculovirus expression vector and cell
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,813,957Engineered oncolytic viruses containing hyper-binding sites to sequester and suppress activity of oncogenic transcription factors as a novel treatment for human cancer
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 18 patents shown.
Pro members see all 18.
Pro members: see all 18 patents
Also on record, not counted in the 18: 8 lapsed for an unpaid fee · 18 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

6 pending · 2 abandoned · 10 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited